Waypoint Capital Advisors’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Waypoint Capital Advisors’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$396K	Hold	4,006	–	–	0.08%	96
2024 Q2	$371K	Buy	4,006 +5	+0.1%	+$448	0.09%	95
2024 Q1	$380K	Hold	4,001	–	–	0.1%	92
2023 Q4	$357K	Buy	4,001 +1	+0%	+$74	0.1%	94
2023 Q3	$292K	Hold	4,000	–	–	0.1%	100
2023 Q2	$333K	Hold	4,000	–	–	0.1%	107
2023 Q1	$305K	Hold	4,000	–	–	0.1%	114
2022 Q4	$332K	Hold	4,000	–	–	0.12%	107
2022 Q3	$317K	Hold	4,000	–	–	0.14%	90
2022 Q2	$297K	Buy	+4,000	New	+$300K	0.13%	92

Other funds holding XBI

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return

Waypoint Capital Advisors's XBI Position: Q3 2024 in Review

Waypoint Capital Advisors held its State Street SPDR S&P Biotech ETF (XBI) position steady in Q3 2024 at 4,006 shares worth $396K. The position accounts for 0.08% of the portfolio, ranked #96.

Waypoint Capital Advisors first reported a position in XBI in Q2 2022 and has held it in 10 quarters since. 769 funds tracked by Wall St. Rank hold XBI as of Q3 2024.

Waypoint Capital Advisors held 4,006 shares of State Street SPDR S&P Biotech ETF worth $396K as of Q3 2024.
Waypoint Capital Advisors left its State Street SPDR S&P Biotech ETF share count unchanged in Q3 2024.
State Street SPDR S&P Biotech ETF made up 0.08% of Waypoint Capital Advisors's portfolio in Q3 2024, its #96 holding.
Waypoint Capital Advisors first reported a position in State Street SPDR S&P Biotech ETF in Q2 2022 and has held it in 10 quarters since.
769 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q3 2024.

Based on Waypoint Capital Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.